Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Exelixis, Inc. < Previous 1 2 3 4 Next > Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial October 04, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 September 10, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 September 07, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September September 06, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update August 09, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 July 26, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer July 11, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies July 07, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference July 05, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer June 21, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies June 16, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June May 31, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 May 26, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 May 26, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May May 04, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer May 03, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022 April 26, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma April 14, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors April 13, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer March 25, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer March 14, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update February 17, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022 February 03, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022 February 02, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 January 18, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 January 09, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor January 06, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma January 05, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 January 04, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.